MedTrace Logo

ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis

NCT05329168 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-06-30

No results posted yet for this study

Summary

This study evaluates safety and tolerability of endolysin-derived LSVT-1701 (tonabacase) as an add-on to standard of care (SOC) antibiotic therapy for the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB), including left- and right-sided infective endocarditis (IE).

Conditions

  • Bacteremia Due to Staphylococcus Aureus
  • Left Sided Infective Endocarditis (Disorder)
  • Right Sided Infective Endocarditis (Disorder)
  • Endocarditis Infective

Interventions

DRUG

Tonabacase (LSVT-1701)

4.5 or 6.0 mg/kg IV once daily for 4 days

Sponsors & Collaborators

  • Lysovant

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-08-17
Completion
2023-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05329168 on ClinicalTrials.gov